Novo Nordisk stock price forecast: $46.50 resistance in focus as NVO extends gains

Traders Union
All News
Financial News
Novo Nordisk gains 1.26% on EU Wegovy news

Highlights

EMA’s panel recommended approving Novo Nordisk’s Wegovy pill in the EU, paving the way for broader market access.
Strong US launch, with over one million prescriptions in four months, highlights high commercial demand for Wegovy.
Technical signals indicate short- and medium-term bullish momentum, but rangebound trading between $43.75–$46.50 is likely short term.

Wegovy approval advances market reach, fueling Novo Nordisk demand

The Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended the approval of Novo Nordisk's Wegovy pill within the European Union, representing a significant regulatory milestone and opening a new pathway for expanded patient access. This move positions Wegovy to reach a broader market, particularly given its established use in the US, where more than one million people received the therapy within four months of launch, illustrating strong commercial uptake and demand. The positive regulatory momentum and clear patient need support current buying interest in Novo Nordisk.

Mixed oscillator signals as near-term strength meets longer-term caution

On the technical front, NVO is trading above its SMA-20 at $44.48 and SMA-50 at $40.56, but remains below the SMA-200 at $49.06. The Ichimoku Kijun sits at $42.91, providing immediate support. Daily MACD signals a strong buy and ADX indicates a strengthening trend, while the weekly MACD and ADX readings turn negative and suggest building pressure. RSI stands at 58.3 with a buy designation, Stoch RSI points to oversold territory, and CCI is neutral, indicating some divergence among oscillators. BBP registers a strong buy and buyers dominate intraday momentum, yet the Awesome Oscillator is neutral, offering no confirmation of the current push. The day’s $0.56 gain came after a small upward gap, with the price testing the top of a modest trading range, showing firm intraday sentiment amid low volatility.

Sideways trade seen as upside breakout odds remain low

For the coming sessions, the typical trading range is projected at $43.75–$46.50, representing a volatility band of approximately ±5% from current levels. There is a low probability (under 20%) of an immediate upside breakout, with underlying conditions favoring a sideways move within this corridor. A decisive move above $46.50 could trigger a test of recent highs, while a breakdown below $43.75 would expose NVO to additional downside risk toward structural supports.

Anton Kharitonov, expert at Traders Union, sees the positive EU regulatory news for Wegovy as supporting sentiment and underlying demand for Novo Nordisk in the near term. Technically, NVO shows active buyers above key short and medium averages but faces resistance and some oscillator divergence, which suggests limited immediate upside. With volatility low and a sideways range favored, Kharitonov believes there is no clear breakout setup yet. "Until $46.50 is broken decisively, my view remains neutral to cautious on further upside here."

Previously it was reported that Novo Nordisk demonstrated short- to medium-term technical resilience amid ongoing selling pressure and awaited catalysts tied to regulatory expansion for Wegovy. The current approval recommendation for the Wegovy pill in the EU adds positive momentum to the stock's outlook, and traders should monitor for a potential breakout above $46.50 as a trigger for renewed directional strength.

Source of Data: NVO Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.